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ABSTRACT 
 
Drug usage, both of a recreational or pharmaceutical nature, is common, however the abuse 
of such substances is an international problem. In the Western cape, South Africa, the burden 
of drug-related fatalities is high compared to the rest of the country. The provincial Forensic 
Pathology Service may encounter cases where drug-related fatalities are unclear whether 
death was accidental or suicidal, or drug toxicity is inconsistent with the medical/social 
history. This may be due to genetic alterations with drug metabolism and it has been 
suggested that genetic analyses may be the next step in these cases. However, toxicology 
results from the National Forensic Chemistry Laboratory in the Western Cape may be 
delayed by months to years, meaning that upon interpretation of toxicology results, there is 
no chance to obtain another blood sample from the deceased individual for genetic analysis.  
It was therefore important to determine the suitability of blood samples collected and handled 
in toxicology environments for subsequent genetic tests. Previously, blood samples from 30 
post-mortem cases were collected into two red-top (no additives), two grey-top (sodium 
fluoride/potassium oxalate) and one purple-top (EDTA) tubes. Samples from one red-top and 
one grey-top tube underwent toxicological analysis, followed by DNA analysis, while the 
remaining tubes (controls) underwent DNA analysis immediately. All samples were then 
stored for approximately one year, prior to this study. The DNA analysis was repeated on all 
blood samples (n = 150) and results were assessed in terms of storage time and tube type. 
DNA was not significantly degraded in any of the samples; however, DNA from red-top 
tubes had significantly lower concentrations compared to that from grey-top tubes (p < 
0.001), regardless of whether the sample had undergone toxicological analysis. The very low 
yields of DNA from red-top tubes posed substantial challenges for PCR-based analysis, 
resulting in poor quality Sanger sequencing results. Some DNA from grey-top tubes, passed 
the quality assessments and hence further work is required to provide an informed decision 
on which tube type is better suited for genetic analyses. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1. Background 
 
The recreational abuse of drugs is a global epidemic (Manchikanti, 2006). South Africa 
experienced a surge in substance-related problems in the nineties, and in 2015 the country was 
reported to be the major trader of illicit drugs in sub-Saharan Africa (Liebenberg et al., 2016) 
In 2009, it was reported that methamphetamine was highly abused within the Western Cape 
(WC) (van Heerden et al., 2009), but more recently cannabis and alcohol use has surged (Dada 
et al., 2014). The WC was ranked second in comparison to other provinces in the country, in 
terms of number of people abusing drugs (SACENDU, 2017). Local mortuaries within the 
province receive numerous cases of unnatural death in which drugs may have caused or 
contributed to death. This is especially the case at the two largest mortuaries, Tygerberg 
Mortuary and Salt River Mortuary (SRM) in the metropolitan region of Cape Town (CT). 
 
SRM is one of the 17 mortuaries in WC, all run by the provincial Forensic Pathology Services 
(FPS) who conduct medico-legal investigations on unnatural deaths based on the National 
Heath Act No. 61 of 2003 (National Heath Act No. 61, 2003) and the Inquests Act No. 58 of 
1959 (Inquests Act No. 59, 1959). SRM receives over 3700 admissions from the West- 
Metropole of CT annually. Biological specimens are collected by the forensic pathologists in 
cases where there is suspicion of drugs, chemicals or other substances contributing to death. 
These specimens usually include blood, vitreous humour, urine, bile, gastric contents and/or 
others. These samples currently undergo toxicological analysis by the National Department of 
Health’s (DoH), Forensic Chemistry Laboratory (FCL) in CT, for the detection of substances 
that may have contributed towards the death. 
 
The interpretation of post-mortem toxicological results is challenging due to the instability and 
post-mortem redistribution of drugs, and can be further compounded by an individual’s genetic 
makeup, which may alter the way drugs are metabolised (Orphanides & Kimber, 2003). This 
is a major challenge in both the pharmaceutical and forensic toxicology fields, in that there is 
limited understanding of inter-individual differences pertaining to drug metabolism (Ingelman- 
Sundberg, Oscarson & McLellan, 1999). Such diversity may lead to effects including failure 
of therapeutic efficacy, adverse drug reactions (ADRs) and even fatality following acute and/or 
chronic drug use (Ingelman-Sundberg, Oscarson & McLellan, 1999). 
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Genetic variants in genes encoding for drug-metabolising enzymes (DME) contribute towards 
this variation in metabolism of drugs (Lynch & Price, 2007). This area of research has become 
known as pharmacogenetics. The term ‘toxicogenetics’ was proposed to relate to the genetic 
differences in metabolic pathways, which result in toxic and/or adverse effects in an 
individual’s responses to xenobiotics. Of particular focus is the cytochrome P450 (CYPs) 
family of enzymes, which metabolise many drugs (Zanger & Schwab, 2013). One of these 
enzymes is CYP2D6, which is responsible for the metabolism of many prescription, licit as 
well as illicit drugs (Druid et al., 1999), and forms a core component of this minor dissertation. 
This purpose of this chapter is to provide an overview of the literature pertaining to the 
background of toxicogenetics, as well as its role in forensics. 
 
1.1.1. Toxicogenetics 
 
Toxicogenetics is the study of heritable alterations in the genome that influence an individual's 
susceptibility to the adverse effects that may result from exposure to exogenous material, such 
as drugs (Park & Pirmohamed, 2001). Response to drug use has been reported to vary with an 
individual’s genotype, with some people of similar age, sex and weight showing different 
responses to drug exposure at similar doses (Meyer & Maurer, 2014). One of the goals of 
toxicogenetic research is to identify genetic markers, such as single nucleotide polymorphisms 
(SNPs), that will predict sensitivity to drug use, as well as the role those drugs and their 
metabolism play in toxicity and/or death (Orphanides & Kimber, 2003). It is recognised that 
ADRs may occur following therapeutic or recreational drug use. The integrated role that ADRs 
and genetic profiles play in death however, is poorly understood. 
 
This area of research, and particularly its application to medico-legal death investigation, is 
relatively new and thus is not yet part of most routine post-mortem procedures internationally, 
including in South Africa. Further research into this field could assist in better understanding 
the role of drug pharmacokinetic variability in death. A toxicogenetic result may hold value for 
family members as it may provide deeper understanding pertaining to the circumstances of 
death and understanding underlying genetic risk factors might help families find closure and 
acceptance of death. These results might also be directly beneficial to families, who may carry 
the same genetic variants as the deceased, and therefore might also be at risk for ADRs. 
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1.2. Cytochrome P450 enzymes: An overview 
 
CYP enzymes are intracellular haemoproteins that activate oxygen for the molecular 
metabolism of lipophilic organic chemicals (Hasler et al., 1999). CYPs are named due to the 
fact that they are bound to membranes within a cell (cyto), and contain a heme (chrome) 
pigment (P) that absorbs light at a wavelength of 450 nm when exposed to carbon monoxide 
(Nebert & Russell, 2002). CYPs are essential for the oxidation of endogenous substances and 
xenobiotics into more hydrophilic compounds (Nebert et al., 1987). CYPs may alter the 
pharmacological profile of many drugs and facilitate their elimination. 
 
Individual CYPs are grouped according to their amino acid similarities and are designated a 
family number, subfamily letter and a number for an individual enzyme within the subfamily 
(Nebert et al., 1987) (Figure 1.1). There are 57 functional genes related to their synthesis in 
humans (Mitani & Otsuka, 2014). There are 18 families and 43 subfamilies of CYPs present in 
humans, with CYP2 being the biggest family (Gopisankar, 2017). Most enzymes in the CYP 
family are polymorphic and allelic variants resulting in altered protein activity may affect drug 
disposition (Zhou, 2009). 
 
CYP2D6*2 
 
 
Cytochrome P450 
 
Family 
 
 
Subfamily 
 
 
Specific 
gene 
Allele 
 
 
Figure 1.1: Nomenclature of CYP enzymes using CY2D6 as an example. An example of 
how CYPs are named; the first three letters (‘CYP’) stand for cytochrome P450, followed by a 
number (e.g. ‘2’) which represents the family the enzyme belongs to. The letter after the family 
depicts a subfamily (e.g. ‘D’), then the specific gene (e.g. ‘6’). Any number after an asterisk 
represents an allele. 
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1.2.1. Factors affecting cytochrome P450 expression and function 
 
Various factors influence the function and expression of CYPs, such as an individual’s 
demographics and their genetic makeup. An individual’s sex has been reported to influence the 
expression of DMEs (Gandhi et al., 2004). Higher levels of protein expression were found to 
be higher in females than in males, suggesting that women may metabolise some drugs faster 
than men (Gandhi et al., 2004). This was widely studied for CYP3A4 but evaluation of sex in 
other members of the CYP family, including CYP2D6, remains to be fully investigated. 
 
Age was also an established factor affecting drug metabolism. Drug metabolism is reduced at 
the extremes of life (Zanger & Schwab, 2013). In infants, this is due to immaturity of CYP 
enzymes, which only become fully developed during the first year of life. In the elderly, drug 
metabolism is reduced, however this may be due to low expression or activity of enzymes 
(Zanger & Schwab, 2013). It has been suggested that reduced rates of metabolism may be due 
to inhibition of enzymes because of drug-drug interactions (Cotreau, von Moltke & Greenblatt, 
2005). Organ dysfunction of liver and kidneys, which may also increase with age, could also 
affect drug metabolism and elimination (Musshoff et al., 2010). 
 
Genetic variants have also been associated with CYP function. The term ‘genetic variant’ refers 
to the occurrence of two or more alleles at a particular locus (Ismail & Essawi, 2012). Genetic 
variants in DMEs are common occurrences and are one of the main causes of inter-individual 
variation of drug effects (Meyer & Zanger, 1997). This inter-individual variation results in 
distinct subgroups in the population that vary in their ability to undergo biotransformation. 
Variants in the genes of the enzymes result in increased, decreased or absent enzyme expression 
or activity (Meyer & Zanger, 1997). CYP2D6 affects the metabolism of over 35 clinically 
used drugs and these include opioids, antidepressants, neuroleptics and antiarrhythmics 
(Meyer, 1996). CYP2D6 is a key enzyme in the metabolism of many commonly used medicinal 
and recreational drugs, many of which are detected in forensic toxicological screening. 
 
1.2.2. CYP2D6 
 
The hepatic enzyme CYP2D6, is vital in the metabolism of certain neuroleptic, antiarrhythmic, 
tricyclic antidepressant and B-adrenoceptor blocking agents (Lennard, 1990). The CYP2D6 
gene is highly polymorphic, giving rise to an enzyme with variable function. Over one hundred 
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allelic variants of CYP2D6 have been identified, which had either fully functional, reduced 
function or non-functional alleles (Kiss et al., 2018). These alleles resulted in four phenotypes 
defined for all CYPs: poor metabolisers (PM), ultra-rapid metabolisers (UM), intermediate 
metabolisers (IM) and extensive metabolisers (EM) (Figure 1.2). An individual’s most 
functional CYP2D6 allele predicts the phenotypic activity. For example, an individual with PM 
and EM alleles will have EM activity (Owen et al., 2009). 
 
 
 
Figure 1.2: Illustration of the CYP2D6 gene and the allelic variants. The duplicated alleles 
(green box) represent the UMs, the functional alleles (pink box) represent the EMs. The yellow 
and blue boxes represent IMs and PMs respectively (Goetz, 2009). 
 
The CYP2D6 enzyme is a polypeptide of 497 amino acids, with a high affinity for alkaloids 
(Zanger, Raimundo & Eichelbaum, 2004). It was reported that the expression of the enzyme is 
different to other hepatic cytochrome P450 enzymes, as CYP2D6 was not regulated by any 
environmental factors or inducible by any known hormones (Ingelman-Sundberg, 2005). 
According to Ingelman-Sundberg (2005), between 20 to 25% of clinically important drugs are 
metabolised in part by CYP2D6 and individuals without functional CYP2D6 genes may 
metabolise certain CYP2D6 substrates at a lower rate, increasing risk for ADR. CYP2D6 
genotyping in post-mortem forensics may provide essential information on whether a variant 
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may have contributed to a drug-related fatality (Sistonen et al., 2005). 
 
 
The CYP2D6 gene is located on chromosome 22q13∙1 (Eichelbaum et al., 1987), spans a 4.2 
kb region, and belongs to a cluster of the pseudogenes CYP2D7 and CYP2D8 (Sistonen et al., 
2005). The gene encompasses nine exons with an open reading frame of 1383 bp coding for 
461 amino acids (Cascorbi, 2003). The most important genetic variations in terms of predicting 
phenotypic activity are splice-site variations, premature stop codons and/or large deletions, 
which resulted in complete loss of enzyme function (Cascorbi, 2003). 
 
Reports have illustrated that drug toxicity either causing or contributing to death, were likely 
due to ineffective CYP2D6 metabolism and elimination of drugs, together with drug-drug 
interactions (Koski et al., 2007). On the contrary, different studies were undertaken to 
determine the impact of studying genetic variants in routine forensic cases. Genotyping of 
CYP2D6 for citalopram metabolism indicated that drug-drug interactions were more important 
than metabolic deficiency (Holmgren et al., 2004). Despite the contradicting results, 
genotyping of CYP2D6 genes remains important, as genotyping of DNA could be used in the 
interpretation of complex and/or contradictory drug-toxicity cases (Levo et al., 2003). The 
following section describes what forensic toxicology entails and the complexities involved 
with interpretation of results, particularly as they relate to post-mortem cases. 
 
 
1.3. Forensic toxicology 
 
Forensic toxicology is a discipline aimed at assisting in the detection, identification and 
quantitation of drugs, chemicals and other xenobiotics in human biological materials, and the 
interpretation of those results for medico-legal purposes (Maurer, 2007). Forensic toxicology 
is applied in numerous areas including post-mortem toxicology, human performance 
toxicology (driving under the influence of alcohol and/or drugs), child welfare and drug- 
facilitated crimes (Ojanperä, Kolmonen & Pelander, 2012). Analyses and interpretation of 
drugs in post-mortem cases can be particularly challenging, due to the interdisciplinary 
knowledge and complex skillset required, particularly within analytical chemistry, toxicology 
and pathology. One of the vital issues with interpretation of post-mortem toxicological results 
is the likelihood of changes in drug concentration after death (Ferrara et al., 2017). The 
variations in drug concentration are a result of degradation of analytes, putrefaction, 
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redistribution and analytical interference with matrices (Skopp, 2010). 
Blood is most routinely collected at post-mortem because it provides insight into the drugs that 
were in the system and therefore may be able to tell something about the role of drugs in 
impairment. However, many pre-analytical factors such as drug stability, re-distribution, 
sample handling and storage require consideration when analysing and interpreting results. 
Given these, blood samples for toxicological analysis are usually collected into sodium fluoride 
(NaF) preservatives (2% w/v) to prevent enzymatic activity and are then refrigerated or frozen. 
Blood samples may also be collected without preservatives if it is suspected that the 
preservative may interfere with the analytes and results. Additional samples such as vitreous 
humour, urine, and gastric contents may also be collected, depending on the interpretive 
requirements in the case. 
 
Collection of samples should be as close to time of death as possible, as drugs tend to degrade 
with time (Dinis-Oliveira et al., 2010). Isolation of chemicals or drugs from post-mortem 
matrices is difficult because of the wide range of specimens encountered (Ferrara et al., 2017). 
Other factors to be considered in post-mortem specimen collection and analysis include how 
and when the drug was administered, history of previous drug use, drug-drug interactions and 
the likelihood of finding the drug in particular specimens (Dinis-Oliveira et al., 2010). Aspects 
such as sampling site(s) and time-related differences in post-mortem drug concentrations also 
have to be taken into consideration when interpreting results (Musshoff et al., 2010). In 
addition, individual pharmacokinetics and/or pharmacodynamics, together with tolerance to 
drugs increases the complexity of interpreting analytical results (Ferrara et al., 2017). This in 
turn makes post-mortem toxicology one of the most challenging disciplines within the forensic 
toxicology field. 
 
Post-mortem toxicology may assist forensic pathologists in determination of cause and manner 
of death (CoD and MoD, respectively) (Druid et al., 1999). Previously, a high parent to 
metabolite (P/M) ratio of a drug was used to distinguish an acute overdose (Druid et al., 1999). 
However, P/M ratios may provide false evidence as low ratios may be encountered in acute 
overdoses (such as in delayed deaths), or high ratios may be encountered as a result of reduced 
metabolism of the parent drug (Nemeroff, Devane & Pollock, 1996). Besides P/M ratios, 
toxicity can also be inferred from post-mortem toxicological results based on contextualisation 
of the case situation. While concentrations of drugs may be suggestive of toxicity; challenges 
may arise in determining the circumstances (and even sometimes the cause) of death if the 
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results are inconsistent with history of use or other case information. This may be important in 
the court’s ultimate determination of the MoD (accident, natural, suicide, homicide or 
undetermined). 
 
Genotyping has been reported to assist in such cases and examples include cases involving 
tramadol and its metabolites, found in 33 post-mortem cases (Levo et al., 2003), as well as 
oxycodone and its metabolites detected in 15 post-mortem cases (Jannetto et al., 2002). In both 
studies it was hypothesised that drug fatalities were partly due to variants in CYP2D6. The 
results showed a correlation between genotype and drug concentrations, suggesting that 
genotyping was useful in some cases by providing a more definitive interpretation of drug 
toxicity. Other variables such as drug-drug interactions might need to be investigated as that 
might assist in determining why ADRs took place (Musshoff et al., 2010). 
 
 
1.4. Toxicogenetics in casework 
 
Toxicogenetic testing has also been applied to other cases and has resolved or added value in 
several instances. For example, a study by Sallee, Devane & Ferrell (2000) was the first to 
demonstrate how CYP2D6 genotyping was useful in explanation of post-mortem toxicology 
results. In the case, a 9-year-old boy diagnosed with extreme behavioural problems and was 
treated with a mixture of psychotherapeutic drugs over a period of 10 months, which included 
three hospitalisations (Sallee, Devane & Ferell, 2000). The boy reportedly died of fluoxetine 
intoxication and very high concentrations of the drug was found during post-mortem 
toxicological analysis. A genetic analysis revealed that the deceased had a totally defective 
CYP2D6 gene, which resulted in poor metabolism and elimination of fluoxetine. It was 
suggested that fluoxetine concentrations had accumulated with therapeutic administration, thus 
resulting in drug toxicity and death. 
 
Another case involved a baby who was found dead 13 days after birth (Koren et al., 2006). The 
baby’s post-mortem did not show any anatomical anomalies, but a blood concentration of 
morphine of 70 ng/ml was reported (Koren et al., 2006). Investigations showed that the baby 
was breastfed by a mother who was receiving codeine. Genotyping was performed on CYP2D6, 
as the CYP2D6 enzyme is responsible for the codeine metabolism to active morphine. The 
mother was found to be heterozygous for CYP2D6*2A, which is classified as a UM. The infant 
had two functional alleles classified as extensive metaboliser. The mother’s genotype led to 
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increased formation of morphine from codeine. The case showed how CYP2D6 variants even 
in mothers, could be life-threatening for babies who are breastfed. This case illustrated how 
genetic analysis may assist to determine why there was morphine in the child and ultimately 
the circumstances and MoD. 
 
In a separate report, it was shown how a CYP2D6 variant was linked to the death of a 43-year- 
old man due to drug toxicity (Koski et al., 2007). The man was found dead on the floor with 
medicinal drugs including fluoxetine, disulfiram and diazepam next to him. Toxicology 
samples taken at autopsy revealed 2.4 mg/L of doxepin and 2.9 mg/L nordoxepin in blood, 
with a ratio of 0.83 between the two and the cause of death was determined to be fatal doxepin 
toxicity. To interpret the doxepin to nordoxepin ratio, CYP2D6 and CYP2C19 genotyping was 
carried out as doxepin is metabolised by CYP2C19. The results revealed a complete absence 
of CYP2D6 enzyme and extensive metabolism in terms of CYP2C19. In a parallel study there 
were 20 cases of fatal doxepin poisoning and the doxepin to nordoxepin ratio was at least 3.8 
(Koski et al., 2006). In the doxepin poisoning case reported above, a defective CYP2D6 
genotype was reported to coincide with the high concentration of nordoxepin found and was 
denoted as contributory to death. 
 
The case examples highlighted above illustrate that toxicogenetic analyses in a post-mortem 
forensic setting may assist in revealing new information on CoD and/or MoD. However, 
toxicogenetic analyses requires considerations associated with both toxicological and genetic 
analyses and are thus not always straightforward. 
 
 
1.5. Post-mortem procedure and collection tubes 
 
The current local post-mortem procedures of unnatural deaths in the WC do not routinely 
include genetic testing. This means that in cases where the CoD and/or MoD is ambiguous 
following ancillary analyses, and where genetic testing maybe the next step, no suitable 
sample was obtained at autopsy for DNA testing. Toxicology testing however, is fairly 
routine in the local post-mortem procedure, whereby blood samples are collected into vials 
containing specific chemicals to preserve the integrity of drugs. These include containers 
such as grey-top tubes, which contain 1-2% w/v NaF as a preservative to prevent bacterial or 
enzymatic reactions, and potassium oxalate (C2K2O4) as an anticoagulant (De Martinis et al., 
2004).
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Plain vacutainers (red-top tubes), containing no preservatives or additives (Penetar et al., 
2008), are also used to collect blood samples where the additives of the grey-top tubes would 
affect the toxicological results. Both of these tubes (red and grey-top) are designed for the 
collection of samples for toxicological and other biochemistry analyses, and not genetic 
analyses, as DNA degrades without suitable preservation (Lahiri & Schnabel, 1993). 
 
For genetic analyses, blood is typically collected into purple-top tubes which contain 
ethylenediamine tetra-acetic acid (EDTA). EDTA binds calcium ions and thus blocks the 
coagulation of blood, providing an optimum environment for DNA preservation in the short 
term, or for longer periods if stored correctly. It was reported that DNA of good quality could 
be extracted from whole blood stored at 4 ºC for one month in EDTA-containing tubes 
(Nederhand et al., 2003). Another study reported that EDTA inhibited the degradation of DNA 
when compared to other anticoagulants, showing that EDTA in the collection tube provided an 
optimal environment for DNA (Lahiri & Schnabel, 1993). Storage time also played a role in 
stability of DNA, whereby whole blood samples in purple-top tubes stored at 4 ºC for one year 
showed a decrease in DNA yield over time (Bulla et al., 2016). 
 
However, due to the post-mortem procedures in the local context, it is not feasible to obtain 
blood in a purple-top tube for every case and store it for months to years, in case a toxicogenetic 
analysis is subsequently needed – which would ultimately be in the minority of cases. 
Currently, the system of toxicological analyses in the country is limited to three National Health 
Forensic Chemistry laboratories. A systematic backlog has developed over time, rendering the 
turnaround time for toxicological results variable – but usually months to years. If case results 
come back after a longer time and genetic testing may be required, it is important to ascertain 
whether the blood obtained for toxicological analyses (i.e. stored in red and grey-top tubes) 
and analysed in a DNA-uncontrolled laboratory, would subsequently be suitable for genetic 
testing. 
 
The NaF preservative contained in the grey-top tubes has been reported to induce DNA damage 
even though the mechanism is unknown (Podder et al., 2015). Fluoride intoxication produced 
specific metabolic alterations in nucleic acid synthesis in the livers of experimental rabbits 
(Jha, Shah & Verma, 2012). The conclusion was that there was reduced DNA in fluoride- 
containing cultured cells. A study was carried out on the effects of fluoride on Vigna radiata 
seeds and showed that there was an increase in DNA damage as fluoride concentrations 
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increased (Agarwal & Khan, 2016). Not only is the presence of NaF a factor that affects 
DNA, but the preservative expires after a certain amount of time. It is unclear what affect this 
would have on DNA recovery once the NaF tubes have expired; however, this investigation 
was outside the scope of this study. The red-top tubes with no preservatives were shown to 
yield DNA of high quality after storage at 4 ºC for sixty days (Lahiri and Schnabel, 1993). To 
the author’s knowledge, there is no published data illustrating the direct effects of C2K2O4 on 
DNA. 
 
To investigate if post-mortem blood samples taken for toxicology could subsequently be used 
for genetic analysis (if necessary), a pilot study was recently undertaken in our research group 
(Vuko, 2017). The quantity, quality and purity of DNA from thirty cases of suspected drug- 
related fatalities was assessed, and it was observed that post-mortem blood samples collected 
into red-top tubes (no preservatives) were suitable for DNA analysis (including DNA 
extraction, polymerase chain reaction (PCR) and Sanger sequencing). This contrasted with 
blood collected into grey-top tubes, which showed low signal and chemical artefacts during 
Sanger sequencing (in-house data). The previous pilot study investigated the integrity of DNA 
16 weeks after collection at autopsy, however in South Africa, there is usually a greater time 
delay between autopsy and government toxicological analyses. Therefore, there is a need to 
explore the effects of storage in these tubes over a longer period of time to better understand 
DNA quality in a locally-relevant situation. 
 
 
1.6. Rationale 
 
In South Africa, determining CoD during post-mortem is one of the main functions of the 
provincial FPS. This is not always straightforward in cases where the individual died in a 
sudden and unexpected manner and drug involvement is ambiguous. In such cases, or in at 
least a subset thereof, death may be linked to underlying variations in the way humans 
metabolise drugs. One way to test for this phenomenon would be to examine the sequence of 
the specific genes encoding the enzymes that are involved in the metabolism of the implicated 
drug(s) (Musshoff, Stamer & Madea, 2010). This may assist in identifying if the deceased had 
a genetically altered metabolism, which induced drug toxicity or reduced the therapeutic 
efficacy of a drug. The present post-mortem procedure does not make provision for such 
toxicogenetic testing. 
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For such a test to be included in the FPS procedure, it must first be ascertained whether the 
blood already/routinely collected at autopsy, will have usable DNA to perform genetic analysis 
after the sample has undergone toxicological analyses and after long-term storage. If not, then 
this motivates for the need to collect an extra blood sample in these situations, specifically for 
DNA analysis, so that suitable biological analyses can be carried out if it is deemed necessary 
downstream. 
 
One may suggest that blood should routinely be collected into purple-top tubes or onto FTA 
cards during post-mortem; however, this would put more pressure on the already resource- 
constrained environment with exceptionally high caseloads. There is also a greater delay 
between autopsy and toxicology analysis in South Africa compared to other countries. It was 
reported that CT and Johannesburg had a backlog of 2878 and 7843 cases, respectively, by 
February 2016, Pretoria had 5013 by January of the same year (Evans, 2016). The national 
backlog was alleged to translate to 5 to 8 years waiting period for toxicology results (Raphaely, 
2011). This study therefore aimed to determine whether blood stored in NaF/C2K2O4 or without 
preservatives (grey and red-top tubes respectively) may be used for subsequent genetic 
analyses (when warranted). 
 
Information collected from this study will assist the pathologists in forensic post-mortem 
investigations, to make an informed decision on whether blood samples collected for 
toxicological testing can later be used for genetic analysis, or if such samples should be 
collected separately, in the case that future testing is warranted. 
 
 
 
 
1.7. Aim 
 
To assess the quantity and quality of DNA from blood samples, which were collected in tubes 
with NaF/C2K2O4 (grey-top tubes) and tubes without preservative (red-top tubes) for 
toxicological screening and stored for one year. 
 
 
1.8. Objectives 
 
To this end, the objectives were to: 
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 Extract DNA from blood samples of 30 cases collected in 2017 which were then stored 
for one year. 
 Assess and compare the quality and quantity of DNA obtained from red, grey and 
purple-top tubes using a variety of molecular methods. 
 Apply statistical analysis tests to assess the suitability of samples for DNA analyses 
compared to results generated one year ago. 
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CHAPTER 2: METHODS AND MATERIALS 
 
2.1. Study population 
 
The study comprised a cohort of 30 cases admitted to SRM between 1st May 2017 and 30th 
August 2017. Informed consent was obtained from each deceased individual’s next-of-kin, 
aligned with an established ethical framework (Heathfield et al., 2017) and is also described in 
detail elsewhere (Vuko, 2017). This study received ethics approval from the University of Cape 
Town (UCT) Human Research Ethics Committee (HREC/REF: 110/2017). 
 
2.1.1. Inclusion and exclusion criteria 
 
Cases selected for this study were those where drugs may have caused or contributed to death, 
or where there was a history of drug use prior to death. The cohort consisted of individuals 
from African (n = 14), European (n = 4), Asian (n =1) and mixed (n = 11) ancestries. There 
were 22 males (age range 22-66) and 8 females (age range 21-57).  Cases where the body was 
found in a decomposed state were excluded, as well as cases where the decedent was below 
the age of 18 years. Full details of the inclusion and exclusion criteria were described 
previously (Vuko, 2017). 
 
 
2.2. Sample collection 
 
For each of the 30 cases, blood samples were collected at autopsy into five tubes: 4 ml blood 
into one purple-top tube (BD Tube, New Jersey, USA), 4 ml blood into each of two grey-top 
tubes (SG Vac, Johannesburg, SA), and 4 ml blood into each of two red-top tubes (SG Vac, 
Johannesburg, SA). 
 
The grey-top tubes contained NaF/C2K2O4, while the red-top tubes had no additives or 
preservatives. Blood specimens collected for toxicological analysis at SRM are commonly 
collected in these containers and thus were the focus of this study. The purple-top tubes 
containing EDTA were used as controls as they are standardly used for genetic analyses. A 
unique identifier code was assigned to each case during the pilot project to maintain 
confidentiality and to track blood samples throughout this study. 
Page | 15 
 
2.3. Brief description of the 2017 pilot project 
 
After sample collection, one red-top and one grey-top tube from each case were designated R- 
Tox and G-Tox respectively. These samples were taken through toxicology laboratory analysis 
as described previously (Vuko, 2017). The remaining red-top and grey-top tubes did not 
undergo toxicological analysis and were thus designated R-No-Tox and G-No-Tox. The 
purple-top tubes also did not undergo toxicological analysis and were designated P-No-Tox. 
All samples underwent DNA extraction as well as DNA quality and quantity assessments 
(Figure 2.1). Full details of these procedures are described in the Master’s dissertation by Vuko 
(Vuko, 2017). After this analysis, samples were stored at 4 ⁰C until this follow up study. 
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Cases (n=30) 
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vacutainers 
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Purple-top 
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DNA analysis DNA analysis 
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analysis DNA analysis DNA analysis 
Deceased 
individual 
2 x Grey-top 
vacutainers 
DNA analysis DNA analysis 
Toxicological 
analysis DNA analysis DNA analysis 
2 x Red-top 
vacutainers 
DNA analysis DNA analysis 
Pilot study 
Present study 
 
 
  
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3-7 days 14-15 weeks 1-7 days 9- 11 months 
 
Average at 16 weeks Approximately 48 weeks 
 
Figure 2.1: Illustration of sample collection and subsequent analyses during the pilot 
project and the current study. The figure shows laboratory procedures after post-mortem 
sample collection, during the pilot and present study. During the post-mortem at SRM, 4ml x 
5 blood samples were collected into 2 red-top tubes, 2 grey-top tubes and 1 purple-top tube 
respectively. R-Tox and G-Tox samples were kept in the UCT Forensic Toxicology Laboratory 
until DNA extraction. The rest of the blood samples underwent DNA extraction after post- 
mortem and were kept in the UCT Molecular Forensics’ laboratory. Sample storage was at 4 
ºC throughout the studies. 
 
 
2.4. Laboratory procedures for the present study 
 
2.4.1. DNA extraction 
 
After approximately 48 weeks following the pilot study, the same blood samples were retrieved 
from storage and DNA was extracted from all samples. This was performed using the QIAamp® 
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DNA Investigator kit (Qiagen, Hilden, Germany), with slight modifications to the 
manufacturer’s protocol. The same modifications were applied during the pilot study (Vuko, 
2017) as follows: for the procedure, 100 µl of blood was eluted into 50 µl of ATE buffer and 
centrifuged at 10 000 rpm for 1 minute and 30 seconds instead of 1 minute. To maximise DNA 
recovery, the elution step was repeated with another 50 µl of ATE buffer, which meant that 
there were two samples of DNA obtained for each tube. The controls used were molecular 
biology grade water (Thermo Fisher Scientific, Massachusetts, USA) stored in purple, grey and 
red-top tubes, which underwent the same DNA extraction procedure as the blood samples. 
 
2.4.2. DNA quantification 
 
2.4.2.1. Quantity and purity assessment of DNA by Nanodrop 
spectrophotometry 
Total genomic quantification of the DNA in this study was performed using the Nanodrop™ 
2000 Spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA). According to the 
Beer Lambert law, there is a direct correlation between absorbance and concentration where 
absorbance (A) = extinction coefficient (Ɛ) x concentration (c) x path length (l) (Desjardins et 
al., 2009). To measure DNA concentration, the instrument was first blanked by placing 2 µl of 
elution buffer ATE (Qiagen, Hilden, Germany) onto the instrument’s pedestal, followed by 2 
µl of each sample thereafter. The results were recorded from the Nanodrop™ 2000/2000c 
software (Thermo Fisher Scientific, Massachusetts, USA). The quantity of DNA as measured 
by Nanodrop™ spectrophotometry was obtained to determine if samples needed dilution prior 
to PCR-based assays downstream. 
To assess purity of the DNA, the absorbance ratios 260/230 and 260/280 were measured by the 
Nanodrop™ 2000 Spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA). A260/280 
is used to determine protein contamination of nucleic acids, while A260/230 shows the presence 
of organic compounds such as aromatic compounds, chaotropic salts and phenol (Desjardins, 
Hansen & Allen, 2009). 
 
2.4.2.2. DNA quality assessment by real-time PCR 
 
Isolated DNA was quantified by real-time PCR (qPCR) to assess the quantity of amplifiable 
DNA, degradation of DNA, as well as cycle threshold (Ct) for the internal positive control 
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(IPC). This was performed using the Quantifiler® Trio DNA Quantification kit (Thermo Fisher 
Scientific, Massachusetts, USA) according to the manufacturer’s instructions. DNA was 
quantified and amplified using the 7500 Real-Time PCR system (Applied Biosystems, 
California, USA). 
 
The Quantifiler® Trio DNA Quantification kit (Thermo Fisher Scientific, Massachusetts, USA) 
simultaneously quantified total human and male DNA in a single reaction. The targets of 
interest were one large autosomal region (214 bp), small autosomal region (80 bp) and one Y 
chromosome region. The assay measures degradation, given as a degradation index (DI), which 
was calculated by dividing the concentration of small autosomal target by the concentration of 
large autosomal target (Köchl et al., 2005). A DI less than or equal to one indicates that DNA 
is not degraded, as amplification was similar between different sized targets. In contrast, larger 
DI indicates that the smaller target could amplify more than the large target, which would 
indicate fragmentation (i.e. degradation) of the DNA. The result from the quantification of the 
Y target was used as an internal quality measure to confirm if DNA amplified was from a male. 
 
The IPC in the Quantifiler® Trio DNA Quantification kit (Thermo Fisher Scientific, 
Massachusetts, USA) is a synthetic DNA template and primer set, which provides positive 
confirmation that all assay components are working correctly. The IPC is also useful in 
identifying samples containing inhibitors. In real-time PCR, a positive reaction is detected by 
accumulation of a fluorescent signal and Ct is defined as the number of cycles for the 
fluorescent signal to cross the threshold (i.e. exceed background level) (Ng et al., 2009). Ct 
values are inversely proportional to the quantity of nucleic acid in a sample, which means lower 
Ct values would indicate less inhibitors in a sample. Therefore, Ct for the IPC of red and grey- 
top samples was assessed to determine if there were PCR inhibitors present, and if this 
parameter changed over time. 
 
2.4.2.3. Application of genetic analysis 
 
The purpose of the study was to determine whether blood samples that were collected for 
toxicological analysis could be used for DNA extraction and genetic analysis thereafter, after 
storage for one year. Therefore, the ultimate test for the suitability of samples for subsequent 
genetic analysis was to apply a molecular assay to the DNA, similar to that which would be 
used in a toxicogenetic analysis. Given that many drugs are metabolised by CYP2D6, the 
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CYP2D6 sequence, which has nine exons, was examined. Primers that amplify these exons had 
been previously designed (Vincent, 2017) and are shown in Appendix A. 
 
One case (number 22) was prioritised for this analysis, because results from toxicological 
analysis showed presence of drugs metabolised by CYP2D6. As such, the genetic results 
would, hypothetically, be of value to such a case (provided the assay was suitably validated). 
The same case was selected during the pilot study, which also facilitated the comparison of 
results. DNA from the red-top and grey-top tubes that had undergone toxicological analysis 
were used for genetic analysis, both during the pilot and this study. 
 
2.4.2.4. Amplification of CYP2D6 exons 
 
Following Sanger sequencing during the pilot study, variations in CYP2D6 were discovered in 
exons 1, 4, 8 and 9 for case 22 (Vuko, 2017). Therefore, PCR was performed for each of these 
exons in the present study to verify if these variants could still be observed one year later. To 
this end, 10 µM of the forward and reverse primers (Integrated DNA Technologies, Iowa, USA) 
were added to 2X GoTaq Green Master mix (Promega, Wisconsin, USA) to amplify DNA 
(maximum volume of 5 µl) in a total volume of 25 µl. 
 
The samples underwent PCR in the BioRad T100 thermal cycler with the following conditions: 
initial denaturation for 5 minutes at 95 ºC; 30 cycles of denaturation at 95 ºC for 30 s, annealing 
at 62.9 ºC (for primers A, C, and I) or 55.3 ºC (for the remaining primers) for 30 s, elongation 
at 72 ºC for 30 s; and final extension at 72 ºC for 5 minutes. 
 
Agarose gel electrophoresis was used to determine if amplification of the targets was 
successful. Agarose powder (Lonza, Basel, Switzerland) was dissolved into 1X Tris-Borate 
EDTA buffer (TBE) and 0.01% (v/v) of SYBR® Safe DNA gel stain (Thermo Fisher Scientific, 
Massachusetts, USA) was added to the mixture to prepare a 1% (w/v) agarose gel. A volume 
of 2 µl of each sample was loaded into the wells, alongside a 1 Kb Plus DNA ladder (Thermo 
Fisher Scientific, Massachusetts, USA). Electrophoresis was performed for 60 minutes at 80 V 
and 400 mA. 
 
In this follow-up study, after PCR, it was noted that amplification of DNA from the red-top 
tubes was poor, and this was attributed to the low yields of DNA obtained. As such, PCR was 
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repeated using the PCR product as the template for a secondary PCR for each region. In the 
secondary PCR, the extension time was increased to 1 min, and cycles increased to 40 for 
exon 1.1 and 8. 
 
2.4.2.5. Sanger sequencing 
 
Sanger sequencing was performed to determine the nucleotide sequences of the amplified 
products, in both the forward and reverse directions. Post-PCR products were cleaned using 
the Nucleofast® 96 PCR Clean-up kit (Macherey-Nagel, Düren, Germany) to remove 
unincorporated primers and dNTPs. Sequencing was performed using the BigDye® Terminator 
v3.0 cycle kit (Applied Biosystems, California, USA) at the Central Analytical Facility at the 
University of Stellenbosch, using their in-house protocol. 
 
The sequences were viewed using Chromas Lite software version 2.6.5 (Technelysium, South 
Brisbane, Australia). The attained sequences were compared to those from the pilot study, as 
well as to the reference CYP2D6 sequence which was obtained from the Ensembl genome 
browser Release 93 (http://www.ensembl.org; accessed 23 July 2018). Alignment was done 
using Sequence Alignment Editor, BioEdit version 7.2.6 using ClustalW with 1000 bootstrap. 
 
Electropherograms (EPGs) were defined as unusable if the calling of nucleotides stopped mid- 
sequence and could not be aligned with the reference sequence. The quality was defined as 
good if all peaks were called, noise to signal ratio was low and could be aligned to the reference 
sequence. Fair was if sequencing in one direction was good and poor in the other direction, 
despite repeating of the poor, and poor quality was if the noise to signal ratio was high causing 
incorrect base pair calling and/or with the distinct presence of chemical artefacts. 
 
 
2.5. Data analysis 
 
The data produced was stratified into three groups, according to the type of tubes that the 
samples were collected in: grey, red and purple-tops. Data from the grey and red-top tubes were 
further divided into two categories: Tox and No-Tox samples. Data analysis was performed 
using Stata® Data Analysis and Statistical Software (StataCorp, Texas, USA). 
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The Shapiro Wilk test was first performed to assess the distribution of data. If there was normal 
distribution, then a one-tailed student’s t-test was used to assess significant differences between 
the median values of the compared datasets (i.e. concentration, DI and purity ratios). If there 
was a non-normal distribution, then the one-tailed Wilcoxon Signed Rank test used to assess 
these differences. In both cases, the Bonferroni’s post hoc test was applied to correct for 
multiple testing. 
 
Since it was found that for all variables (i.e. concentration, DI and purity ratios), data from test 
Tox and No-Tox samples for a specific tube type were not significantly different, these data 
were combined for red and grey-top tubes, respectively, for multiple regression analysis. This 
test was performed in attempt to model the relationship between (i) time since blood sample 
collection at autopsy, (ii) tube type (red and grey), and (iii) concentration or DI or purity ratio. 
Heteroscedasticity was analysed by residual versus fitted plots, and the Breusch-Pagan test and 
robust methods were used to counteract low heteroscedasticity. This test is used to assess 
whether the variance of the error of terms is dependent on the independent variable, which in 
this case, was tube type. The level of significance (฀) was 0.05. 
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CHAPTER 3: RESULTS 
 
3.1. Introduction 
 
DNA was extracted from the stored blood samples (n = 150) after 48 weeks of storage; i.e. 
from all five collection tubes from all 30 cases. After extraction, the quality and quantity of 
DNA was assessed using qPCR. Data were sorted according to (i) collection tube type and (ii) 
analyses performed i.e. R-No Tox, R-Tox, G-No-Tox, G-Tox and P-No-Tox. Median values 
of DNA concentration (ng/µl), purity ratios and DI were calculated to represent the data. 
Appendix B shows the summarised data. 
 
 
3.2. DNA concentration 
 
DNA quantification after 48 weeks by qPCR showed that blood samples from G-No-Tox had 
the highest median DNA concentration of 37 ng/µl, followed by G-Tox samples with 21 ng/µl 
(Figure 3.1). The difference between the grey-top tubes (G-No-Tox and G-Tox) was however 
not significant (p = 0.05). The red-top tubes had the lowest median concentration with 0.8 ng/µl 
(R-No-Tox and R-Tox). Comparison between R-No-Tox and R-Tox (intra-tube) showed that 
there was no significant difference in qPCR concentration (p = 0.87). The purple-top tubes had 
a concentration of 7.5 ng/µl and this was significantly higher than the red tubes (p = 0.01). 
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Figure 3.1: DNA quantification after 48 weeks by qPCR. Blood samples were collected into five 
vacutainers: two red, two grey and one purple-top. The samples were assessed for DNA quality and 
quantity and stored for approximately 48 weeks at 4 ⁰C. After 48 weeks, DNA was extracted from all 
blood samples using the QiaAmp® DNA Investigator kit (Qiagen, Hilden, Germany), followed by DNA 
quantification. 
 
 
There was no significance difference in terms of DNA concentration between tubes of the same 
colour i.e. R-No-Tox vs R-Tox and G-No-Tox vs G-Tox and therefore the results for Tox and 
No-Tox samples for each tube type were combined for further statistical analysis. DNA 
concentration was assessed over time for red-top and grey-top samples and, as expected, the 
DNA concentration decreased over time for red-top samples, and this correlation was 
significant (r = -0.24, p < 0.001) (Figure 3.2). However, DNA concentration appeared to 
significantly increase with time for grey-top samples (r = 0.21, p = 0.017), which was 
unexpected. A linear regression analysis, which modelled concentration based on tube type and 
time in weeks (i.e. time between blood collection at autopsy and DNA extraction), showed that 
time and tube type accounted for 14% of the variance in concentration (p < 0.001). The 
following equation was established to model DNA concentration based on these two variables: 
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DNA concentration = 0.74 (tube type) + 0.019 (weeks between blood collection at autopsy 
and DNA extraction) + 0.25 
 
2 5 0 
r e d tu b e 
 
2 0 0 g r e y t u b e 
 
 
1 5 0 
 
 
1 0 0 
 
 
5 0 
 
 
0 
0 2 0 4 0 6 0 
T im e in w e e k s 
Figure 3.2: DNA concentration over time. DNA concentration for red and grey-top tubes was 
combined for Tox and No-Tox samples and assessed over time. The figure illustrates data from the 
pilot study (0 -16 weeks) and data from the present study (after 40 weeks). Time was calculated as 
date of sample collection at post-mortem examination to date of DNA extraction. 
 
 
 
 
As indicated above, DNA concentration for grey-top tube samples unexpectedly increased over 
time. To explore this further, and in an attempt to explain this trend, the Ct values for the IPC 
of each red and grey-top sample were assessed to compare the possible presence of PCR 
inhibitors in these samples, and if these changed over time. If PCR inhibitors decreased with 
time, this would manifest as an apparent increase in DNA concentration measured using a PCR- 
based method. However, contrary to this hypothesis, the results showed an increase in the IPC 
Ct values for grey-top tube samples. This meant that PCR inhibitors actually increased over 
time and could not be the reason for the apparent increase in DNA concentration over time 
observed in the DNA from grey-top tubes (Figure 3.3). The IPC Ct value for red-top tubes were 
as expected. 
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Figure 3.3: Ct values for the IPC over time in weeks. Ct values for the IPC for red and grey-top 
top samples were assessed to determine the amount of PCR inhibitors present in the sample over 
time. Time in weeks from 0 to approximately 16 weeks represents the pilot study and data after 40 
weeks represents the present follow-up study. 
 
 
 
3.3. Assessment of DNA quality 
 
3.3.1. DNA degradation 
 
The Quantifiler® Trio DNA Quantification kit (Thermo Fisher Scientific, Massachusetts, USA) 
measured the concentration of large and small autosomal DNA targets. DI was then calculated 
for all samples after 48 weeks and was used as a measure of DNA quality (Figure 3.4). P-No- 
Tox samples showed the highest DI (median = 1.2), followed by R-No-Tox and R-Tox with 
median values of 1.10 and 1.07 respectively. Grey-top samples showed the lowest DI with 0.8 
for G-No-Tox and G-Tox with 0.9. There was no significant difference between G-No-Tox vs 
G-Tox (p = 0.086) as well as between R-No-Tox vs R-Tox (p = 0.14). Although the purple-top 
tubes had the highest DI, it should be noted that it was not significantly higher than the other 
samples, nor did it compromise the ability of molecular analysis in those samples. 
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Figure 3.4: Assessment of DNA quality by measure of degradation index after 48 weeks. 
Degradation index was calculated by dividing concentration of small autosomal and large autosomal 
DNA targets, for each sample type. Quantification of the autosomal targets was performed with the 
Quantifiler® Trio DNA Quantification Kit (Thermo Fisher Scientific, Massachusetts, USA). 
 
 
Degradation was assessed 48 weeks after sample collection at autopsy and compared to data 
from the pilot study, for red and grey-top tubes, and an increase in DI was observed for both 
sample types over time (Figure 3.5). In this study, 34/60 (57%) red-top and 22/60 (37%) grey- 
top samples had a DI between 1 and 5, indicating that DNA in these samples were slightly 
more degraded compared to the pilot study. There was also a single sample from a red-top tube 
with a much higher DI of 9.9, indicating that this sample was indeed degraded. Other than this 
sample, DNA degradation was not a concern after 48 weeks. 
 
Overall, there was a positive correlation between time and DI, for grey-top samples (r = 0.01, 
p = 0.85) and red-top samples (r = 0.42, p < 0.001). A linear regression model found that 13% 
of the variance in DI could be explained by the tube type (additives in the tube) and time 
between blood collection at autopsy and DNA extraction (p < 0.001). The following equation 
was obtained to model DI based on these two variables: 
 
DI = 0.018 (tube type) - 0.003 (weeks between blood collection at autopsy and DNA 
extraction) + 1.13
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Figure 3.5: Degradation index over time. DNA degradation for red and grey-top vacutainers (Tox 
and No-Tox) was combined and assessed at 16 weeks and after 48 weeks (pilot and follow-up study 
respectively). Time was calculated from date of sample collection at autopsy to date of DNA 
extraction. 
 
 
3.3.2. DNA purity 
 
DNA purity was assessed by measuring absorbance at 260, 230 and 280 nm. Purity ratios were 
then calculated from the three wavelengths i.e. A260/280 and A260/230. In this follow-up study, 
the highest purity ratio for A260/280 was observed with the G-Tox samples (median = 1.74), thus 
indicating the best purity. There was no significant difference between Tox and No-Tox 
samples for grey-top samples (p = 0.15). A260/280 for red-top (median = 1.5) and purple-top 
samples (median = 1.5) were also below the threshold of 1.8, as indicated by dotted line in 
Figure. 3.6. Red and grey-top samples showed a decrease in A260/280 over time, which indicated 
the increasing presence of protein contaminants, or the decreasing concentration of DNA; the 
latter which is perhaps more likely (particularly with red-top tubes). This correlation was 
significant (r = -0.55, p < 0.001 and r = -0.31, p < 0.001), respectively. A linear regression 
showed that 13.2% of the variance in A260/280 could be explained by tube type and time between 
blood collection at autopsy and DNA extraction (p < 0.001). The overall equation was as 
follows: 
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A260/280 = 0.04 (tube type) + 0.0017 (weeks between blood collection at autopsy and DNA 
extraction) + 0.73. 
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Figure 3.6: DNA purity ratio A260/280 for blood samples measured after 48 weeks. 
Following DNA extraction, samples were assessed for purity by measuring absorbance 
at 260 and 280 nm using the Nanodrop™ 2000 spectrophotometer (Thermo Fisher 
Scientific, Massachusetts, USA). 
 
 
 
The highest A260/230 purity ratio was observed with grey-top samples (median 1.2 for G-No- 
Tox followed by 1.1 for G-Tox). Red-top samples showed the lowest A260/230 ratios with median 
values of 0.72 (R-No-Tox) and 0.61 (R-Tox). There was no significant difference between Tox 
and No-Tox samples for grey-top samples (p = 0.5), but for red-top samples there was a 
significant difference (p = 0.06). All samples fell below the threshold of 2, as shown by the 
dotted line (Figure 3.7). The decrease in A260/230 for red and grey-top samples showed a 
significant correlation (r = -0.61, p < 0.001 and r = -0.31, p < 0.001), respectively. A linear 
regression analysis modelled A260/230 based on time between blood collection at autopsy and 
DNA extraction and tube type and showed that the variables accounted for 38.9% of the 
variation seen in A260/230. The overall equation was as follows: 
 
A260/230 = 0.020 (tube type) + 0.0059 (weeks between blood collection at autopsy and DNA 
extraction) + 0.74 
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Figure 3.7: DNA Purity ratio A260/230 after 48 weeks (follow-up study). DNA purity 
was determined by Nanodrop™ 2000 (Thermo Fisher Scientific, Massachusetts, USA). 
Absorbance was measured at 230 and 260 nm and purity ratios calculated thereafter. 
 
 
 
3.3.3. Sanger sequencing 
 
Lastly, DNA suitability for toxicogenetic analysis was assessed by Sanger sequencing. Exons 
1, 4, 8 and 9 were amplified by PCR, after which agarose gel electrophoresis was performed to 
confirm amplification. The PCR product was used as a template for secondary PCR in red-top 
tube samples due to low concentrations of DNA obtained from those samples. DNA sequencing 
EPGs were then compared in terms of background noise and ability to accurately distinguish 
SNPs. The expected amplicon sizes were as follows: exon 1.1: 954 bp; exon 1.3: 314 bp; exon 
4: 266 bp; exon 8: 534 bp and exon 9: 520 bp. All the exons eventually amplified successfully 
(Figure 3.8). 
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Figure 3.8: Agarose gel showing PCR amplification of CYP2D6 targets. Amplification was 
performed for regions 1.1, 1.3, 4, 8 and 9 for red and grey Tox samples. From left, well M: 1Kb 
Plus DNA ladder (Thermo Fisher Scientific, Massachusetts, USA), N: no template control, A-E: 
targets 1.1, 1.3, 4, 8, 9 respectively for grey-top samples. A1-E1 represented the same targets 
for red-top samples. Electrophoresis was performed at 80 V, 400 mA for 60 minutes. 
 
 
 
 
DNA sequence alignments for red and grey-top samples were compared following Sanger 
sequencing. The overall results, in this follow-up study, showed that grey-top samples 
produced EPGs that were of better quality than red-top samples, in terms of background noise 
and chemical artefacts. EPGs were of poor quality for exon 1.1 (954 bp) for the red-top tube, 
while for the grey-top it was of fair quality. EPGs for exon 9 (520 bp), for both red and grey- 
top tubes were unusable; while EPGs were of fair quality for exon 1.3 (314 bp) and 8 (534 bp) 
for the red-top samples. Exon 4 (266 bp) was the only region which produced good quality 
EPGs for both red and grey-top samples and showed the same variations as observed during 
the pilot study. Overall data was good for the grey-top tubes in three instances, while it was 
poor, fair or unusable for red-top samples. As expected, there were no new artefacts or 
variations observed in any of the EPGs of good quality. Table 3.1 below summarises the quality 
of the Sanger sequencing results, alongside those results from the pilot study. 
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Table 3.1: Comparison of EPG quality in 2017 and 2018 
 
Region Size (bp) Red-top tube Grey-top tube 
2017 2018 2017 2018 
4 F 266 Good Good Good Good 
4 R Good Good Good Good 
1.3 F 314 Good Poor Good Good 
1.3 R Good Good Poor Good 
9 F 520 Fair Unusable Poor Unusable 
9 R Fair Unusable Fair Unusable 
8 R 534 Good Fair Good Good 
1.1 F 954 Good Unusable Good Poor 
1.1 R Fair Unusable Fair Good 
Table 3.1: EPG quality at 16 weeks (2017) and 48 weeks (2018) after sample collection at 
autopsy. After quantification, DNA suitability for toxicogenetic analysis was assessed using Sanger 
sequencing. Results from the pilot study were then compared to results obtained in the follow-up 
study. 
 
 
In summary, red-top samples had 4 EGPs which were unusable and one 1 poor, compared to 2 
unusable and 1 poor in grey. But overall, out of the 5 regions, 2 were unusable for red, and only 
1 unusable for grey. 
 
Figure 3.8 below shows exon 1.3 for grey and red-top samples to illustrate good and poor - 
quality EPGs (respectively). The rest of the DNA sequences are shown in appendix C. 
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Figure 3.9: A portion of DNA sequence for exon 1.3 for (A) grey- and (B) red-top 
samples. Following DNA extraction in the follow-up study, five targets of CYP2D6 were 
amplified using case 22 red and grey-top samples that had undergone toxicological analysis. 
The samples were then sent to the Central DNA Sequencing Facility at the University of 
Stellenbosch for sequencing. A represents grey-top while B represents red-top samples. 
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CHAPTER 4: DISCUSSION 
 
The aim of this research was to determine if blood samples collected into NaF/C2K2O4 and 
plain tubes (grey and red-top respectively) for toxicological analysis could be used for 
subsequent genetic analyses, should that be warranted as the next step of ancillary 
investigations to determine CoD and/or MoD. In this phase of the longitudinal study, the focus 
was DNA suitability for genetic analysis 48 weeks after sample collection, and to compare 
results to those obtained initially. This study was situated in a larger study, which aims to 
investigate the potential and future use of toxicogenetic analysis in local post-mortem 
examinations. This was motivated by the genetic analyses of DMEs related to ADRs and death, 
which have shown value in aiding CoD and/or MoD in other countries (Levo et al., 2003). It 
is therefore important in our context to determine if the blood samples already collected for 
toxicological analyses would be suitable for subsequent genetic analysis; as opposed to 
collecting an additional sample for DNA analysis in every case – and it only being needed in 
the minority of cases. 
 
 
4.1. DNA concentration 
 
DNA concentration must be estimated accurately before any downstream analyses such as 
DNA profiling or sequencing (Yu et al., 2017). DNA quantification by Nanodrop™ 2000 
spectrophotometry (Thermo Fisher Scientific, Massachusetts, USA) was performed to 
determine if there were samples that required dilution prior to qPCR. qPCR is a very sensitive 
and specific DNA quantification method, which specifically measures the amount of 
amplifiable DNA (Köchl, Niederstätter & Parson, 2005). Accurate quantification of DNA in a 
forensic sample makes it possible to adjust its concentration for downstream analysis such as 
for genotyping or sequencing (Nielsen et al., 2008). 
 
The decrease in DNA concentration observed for red (Figure 3.2) and purple-top tubes 
(Appendix B), after 48 weeks, could possibly been have influenced by post-mortem cell death. 
Cell death occurs via a process known as necrosis, which is characterised by swelling of 
cytoplasmic organelles, increased cell volume and condensation of chromatin (Alaeddini, 
Walsh & Abbas, 2010). This is then followed by the rupture of membranes and spilling of 
lysosomal enzymes into cellular compartments. These effects have been observed in stored 
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whole blood (Alaeddini, Walsh & Abbas, 2010), suggesting that this may have been a plausible 
mechanism for the DNA loss observed in this study. 
 
Independent of whether blood samples had undergone toxicological analysis or not, the 
concentration of DNA isolated from blood that was stored in grey-top tubes was the highest 48 
weeks later. This was in comparison to DNA concentration from purple and red-top tube 
samples at the same time point (Figure 3.1). There were significant differences in DNA 
concentration between each tube type; thus, it was postulated that the additives in the different 
tubes played a role in altering DNA concentration. 
 
Purple-top samples were stored in EDTA, which was recommended as the anticoagulant of 
choice as it inhibited DNAse activity and is reported to not alter quantity of DNA if stored 
appropriately, such as in the freezer for long-term (Kotikalapudi & Patel, 2015). Several 
guidelines for optimal DNA storage for DNA extraction have been reported, to allow for 
genetic studies to be conducted over a long period of time (Gomma & Fox, 2001). DNA was 
reported to be more stable under long-term freezer storage and storage in buffy coats, which 
are aliquots of white blood cells (Mychaleckyj et al., 2011). Another study also investigated 
the effect of temperature and storage time on blood samples stored in EDTA. The results 
showed that extracted DNA was of high quality after storage at 4 ºC for a maximum of one 
month (Nederhand et al., 2003). Although EDTA tubes were used for the controls in this study, 
these samples were stored at 4 ⁰C and not frozen for one year. This was to expose the controls 
to the same conditions as those experienced by the other tubes so as to minimise variability. 
However, the prolonged storage of samples in purple-top tubes under conditions which are 
perhaps not the most ideal, could therefore explain the decreasing DNA concentrations, as 
well as DNA concentrations that were lower than the grey-top tubes. 
 
The red-top tubes contained no additives, suggesting that it had no added protective measure 
against DNA damage. There has been research investigating the effect of storing whole blood 
without preservatives for DNA fingerprinting. In a study performed over a period of eight 
weeks, blood was stored in tubes with either EDTA, heparin or without the anticoagulants at 
room temperature, 4 ⁰C, -20 ⁰C and -70 ⁰C (Bomjen et al., 1996). The results showed that DNA yield 
was better in blood samples stored with anticoagulants (EDTA or heparin) and at colder 
temperatures (Bomjen et al., 1996). It has been reported that prolonged storage of whole blood 
causes lysis of white blood cells (WBC) resulting in DNA loss during the WBC harvesting step 
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of DNA extraction (Nederhand et al., 2003). This process seemed to be slowed by the presence 
of additives, EDTA or heparin (Bomjen et al., 1996). Hence the significant decrease in DNA 
quantity observed in red-top tubes in this study (p = 0.01) could be attributed to the lack of 
additives in the tube. 
 
Grey-top tubes, containing NaF preservative and C2K2O4 anticoagulant exhibited the highest 
DNA concentrations (for both Tox and No-Tox samples) in comparison to red and purple-top 
samples. There have been studies to show effect of fluoride on DNA degradation, however no 
studies could be found to show effect the of fluoride on DNA concentration. In this study grey- 
top tubes had the highest DNA quantity, compared to standard purple-top tubes after 48 weeks 
of storage. Regression analysis showed that time and tube type could only explain 14% of the 
variation in concentration, where time accounted for the majority (9.6%) of the variance. This 
therefore suggested that other factors were at play. This then prompted the assessment of Ct 
values of the IPC over time (between 16 and 48 weeks) to determine if PCR inhibitors could 
explain the observed results for grey-top tubes. 
 
It was thought that the apparent increase in DNA concentration in grey-top tubes may be due 
to a decrease in PCR inhibitors. It was speculated that in 2017, there were inhibitors present in 
the blood samples, which therefore underestimated DNA concentration, and with time the 
inhibitors may have decreased, showing an apparent increase in DNA concentration. However, 
this was not the case, as the analysis of the Ct values of the IPC showed an increase of PCR 
inhibitors over the 48-week period. Although it was not the primary objective Nanodrop™ 
spectrophotometry, DNA concentration was measured for all samples, which also confirmed 
the overall increase in DNA concentration for grey-top samples (data not shown). This 
provided further evidence that the apparent increase of DNA concentration as measured by 
qPCR was indeed not due to a decrease in PCR inhibitors. 
 
These results then point to the possibility of more DNA being extracted from the vials in this 
study compared to the pilot study. This may have been due to the chemicals present in the grey- 
top tubes which may have interacted with reagents during the DNA extraction process 
differently over time. To investigate this hypothesis and the possible chemical interactions was 
beyond the scope of this minor dissertation, but warrants further investigation to better 
understand the trends observed in this study. 
Page | 36 
 
Lastly, inter-user variability between the two studies may have been a reason for the apparent 
increase of DNA concentration in samples stored in grey-top tubes. It is possible that there 
were slight differences in the DNA extraction protocol or even the preparation of standards or 
sample dilution for qPCR, resulting in the results observed. For example, more DNA could 
have been extracted during the present study, as a result of inverting the blood collection tubes 
more. If this was the case, a systematic trend across all tube types would be expected, but the 
increase in DNA concentration was only (and consistently) observed in grey-top tubes. 
However, user variability cannot be excluded totally as a contributory factor in the apparent 
increment in DNA concentration for grey-top tube samples. 
 
4.2. Assessment of DNA quality by purity ratios 
 
Analysis of both purity ratios showed decreases in DNA purity over time for all tube types 
(Figure 3.6 and Figure 3.7), with the decrease in A260/230 being greater than the decrease in the 
A260/280 ratio. A regression model for A260/230 based on time and tube type showed that 38.9% 
of the variance in this ratio could be explained by tube type and time and this percentage 
variance was the highest for all variables investigated. 
While both purity ratios for all samples were below the accepted thresholds of 1.8 and 2, 
samples from the grey-top tubes were the purest compared to the other tube types. The additives 
in the various tubes must also be considered within the context of spectrophotometry 
interpretation. For example, EDTA and C2K2O4 absorb UV at 230 nm (Bhattacharyya & 
Kundu, 1971; Soga & Ross, 1999) which may have contributed to the absorbance at 230 nm 
measured in this study, particularly if it was not sufficiently removed during the DNA 
extraction process. Although EDTA alone does not absorb UV light at 230 nm, the interaction 
with iron (Fe2+) found in blood does (Bhattacharyya & Kundu, 1971). 
 
As such, the A260/230 purity ratio would be representative of not only the traditional chaotropic 
salts and carbohydrates known to absorb light at 230 nm and to be involved in the sample 
and/or DNA extraction process, but also from the EDTA or C2K2O4 from the purple-top and 
grey-top tubes, respectively. NaF has a maximum absorbance at 500 nm (Farajzadeh, 2004), 
and thus was unlikely to have affected the purity ratios measured in this study. However, it still 
may have decreased the overall purity of the sample but was not measured using the 
spectrophotometry method. The use of spectrophotometry therefore was a limitation of 
measuring sample purity in this study. 
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4.3. Assessment of DNA quality by degradation index 
 
Analysis of degraded DNA is a common challenge in forensics due to the wide range and 
quality of samples encountered. The Quantifiler® Trio DNA Quantification kit (Thermo Fisher 
Scientific, Massachusetts, USA) measures the quantity of small and large autosomal targets, 
the ratio of which is used to assess degradation (Köchl et al., 2005). Samples are not degraded 
if the small and large fragments amplify equally. However, if the smaller fragments amplify 
better than the large fragment, then a DI > 1 is observed, meaning there is a greater degradation 
of the DNA. Research has shown that when DI > 4, challenges may be encountered in 
downstream assays where amplification of fragments larger than 300 bp is necessary (Köchl et 
al., 2005). 
 
The average DI for all samples in the pilot study (i.e. approximately 16 weeks from sample 
collection at autopsy) were below 1, suggesting that DNA was intact and not degraded (Figure 
3.5). Measurement of DNA extracted after 48 weeks showed that DI increased slightly to a 
median of 1.2, which was the highest for purple-top tubes. Red-top tubes had a median DI of 
approximately 1, whilst the grey top-tubes recorded the lowest index of 0.8. Although there 
was a significant increase in DI for red-top (p < 0.001) and grey-top tubes (p = 0.02) (Figure 
3.5), the DI surrounding 1 meant that DNA was generally not degraded for any sample type 
after 48 weeks. The exception was one outlier, for red-top tubes, with a DI of 9.9 and was 
probably due to the drugs found in the system. 
 
There have been studies showing that NaF induces DNA damage in rat kidneys (Ning et al., 
2009), however there was limited information on the mechanism of this fluoride-induced cell 
death. One option put forward was that fluoride led to an increase in Ca2+ in different cell types 
and that this increase was proposed to induce apoptosis (Trump & Berezesky, 1992). In another 
study, fluoride was shown to induce DNA damage in human carcinoma cells (Verma, Daoud 
& Pathak, 2017). These data suggest that fluoride does have an influence on DNA damage or 
degradation thereof, which means more work is required to investigate the effect of fluoride on 
human DNA. There was no data to show effect of C2K2O4 on DNA as the two (NaF/C2K2O4) 
together might change the way NaF interacts with DNA. 
 
Although purple-top tubes are the standard collection tubes for genetic analyses, DNA 
degradation was highest in these tubes, although not significantly higher than those from red 
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and grey-top tubes. This was likely attributed to the effect of storing blood at 4 ºC whereby 
DNA quality has shown to decrease at this temperature over time, even when stored in Tris- 
EDTA (TE) buffer (Richardson et al., 2006; Lahiri and Schnabel, 1993). 
 
A regression model showed that storage time and tube type could explain 14% of variations 
seen in DI. This again suggests that other factors are at play, such as age, sex and post-mortem 
interval. The assessment of these variables again fell out of the scope of this investigation, but 
will be considered in future work. 
 
 
4.4. Sanger sequencing 
 
In this study, post-mortem blood samples collected in grey-top and red-top tubes were analysed 
for suitability to perform toxicogenetic analyses. Toxicogenetics focuses on the genetic 
variations in genes responsible for drug metabolism. CYP2D6 is involved in the metabolism 
of many toxicologically important drugs and genotyping for this enzyme resulted in 
polymorphic distributions in various populations examined (Druid et al., 1999). CYP2D6 
genotyping is considered a valid technique to determine metabolic status (Sistonen et al., 
2005). In this study, genotyping would assist in determining the metabolic status of the 
deceased and contextualise as to whether any drugs detected may have been affected by these 
metabolic alterations. 
 
The purpose of this analysis in this study was to amplify DNA in one selected case from the 
cohort, specifically the target regions where SNPs were observed previously, and compare the 
results from this analysis to those obtained in the pilot study (Vuko, 2017). The pilot study 
showed that good sequencing data was consistently obtained from the red-top tube samples, 
whereas many artefacts were observed in EPGs from DNA from the grey-top tubes. The 
purpose of repeating the sequencing analysis in this study was two-fold: first, to determine 
whether the assay could be carried out on samples with lower concentrations and increased 
degradation of DNA (red-top tubes) and (ii) if the assay would still produce reliable results 
approximately one year later. This was important considering the long delays in receiving 
toxicological results in the local context and therefore possibility of initiating a toxicogenetics 
analysis. Only after toxicology results are returned, would genetic analysis be requested, which 
could be some time (e.g. months to years) later from the FCLs. 
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Quantity and quality assessment showed a significant decrease in concentration and purity 
ratios and an increase in DI for red-top tubes, which was consistent with the challenges 
experienced in analysing these samples using PCR and sequencing methods. The PCR assay 
was re-optimised for red-top tubes due to their significantly lower concentration as compared 
to the pilot study (Vuko, 2017) (Figure 3.2). Upon initial performance of the original assay, 
samples from red-top tubes showed faint bands on the agarose gel (Appendix D) and during 
sequencing, had a very low signal to noise ratio. Amplification was better for the smaller 
fragments. To overcome this challenge, a secondary PCR was carried out for larger exons, with 
altered PCR conditions, as described in Chapter 2. 
 
Despite these improvements, EPGs from red-top samples were still of slightly poorer quality 
compared to matched exons from grey-top tubes. The poorer performance of the red-top tube 
samples was attributed to the very low concentration of DNA observed 48 weeks after sample 
collection (median = 0.09 ng/µl), compared to 16 weeks after sample collection (median = 17.4 
ng/µl). While red-top tube samples were more degraded over time in general, the median DI of 
this sample of interest was 1.7, which indicated only slight degradation, and this was probably 
not a factor for poorer sequencing. However, if blood samples from red-top samples were the 
only samples available, an attempt could be made to perform toxicogenetics analysis, but the 
target amplicons need to be kept small and a DNA polymerase which is sensitive to low copy 
number DNA must be used. It is also anticipated that with increased age of the samples, issues 
with Sanger sequencing may become more complex, and the procedure may require further 
optimisation. This might include the adjusting of magnesium (Mg2+), a cofactor of Taq 
polymerase, and/or the adjustment of pH of the PCR buffer. 
 
Assessment of grey-top tube samples in the pilot study showed EPGs with chemical artefacts 
(Vuko, 2017), which was not the case at 48 weeks. EPGs for two regions (exons 4 and 8) 
remained the same good quality over time, and the EPGs for exon 1.3 improved in quality over 
time (i.e. poor to good). The improvement may have been due the higher concentrations of 
DNA obtained from the samples in this study, or perhaps due a decrease of chemical 
interactions from the additives in the grey-top tubes (which was not investigated further in this 
study). The sequencing of exon 9 was problematic in both the red and grey-top tube samples, 
and was of poor or fair quality in the pilot study too, suggesting that this result might be region- 
specific, as opposed to tube-type related. A closer analysis of the primers and possible variants 
within the primer binding regions need to be assessed in this case example in the future. The 
Page | 40 
 
relatively good quality sequencing results from this study are in accordance with a previous 
study by Druid et al. 1999, where CYP2D6 genotyping was successful on femoral post-mortem 
whole blood, where EDTA, heparin and NaF was added (Druid et al., 1999). 
 
The final region sequenced in this study was the first portion of exon 1 (named exon 1.1) and 
the EPG from the grey-top tube decreased in quality compared to that obtained in the pilot 
study. The reason for this observation was that slightly different primer sets were utilised in 
this study which resulted in a larger fragment of DNA being amplified here. During the pilot 
study, primer set for exon 1.1 targeted a fragment of 439 bp. However, subsequent to this, 
genetic variations were found in the primer binding region for the reverse primer, resulting in 
failed amplification in some samples. Therefore, a new reverse primer was designed, but to 
mitigate non-specific binding, it resulted in an amplicon of 954 bp (Vincent, 2017). The 
decrease in EPG quality for this fragment was thus attributed to the larger amplicon size and 
not type tube. 
 
It is not always easy to amplify short target sequences with CYP2D6 due to presence of 
pseudogenes (Gaedigk, 2013) and non-specific binding. Next generation sequencing (NGS) 
thus might be useful in this regard as it reads a large number of short fragments in a high- 
throughput and parallel manner, with a read length of about 35-500 bp (Zhang et al., 2011). 
Since NGS technology is rapidly increasing the speed of throughput capacities for DNA 
sequencing, it is also becoming more affordable (Schuster, 2008). 
 
While overall sequencing of DNA from grey-top tubes was better than that from red-top tubes 
in this study, such a conclusion cannot be made based on such small sample sizes. It would be 
important to sequence all nine exons of CYP2D6 and on a statistically significant number of 
cases to get a realistic indication of which tube type(s) would be suited for this analysis. This 
study has nevertheless provided important insight into the unexpected results if improved 
results from grey-top tubes with time, as well as some of the challenges encountered when 
dealing with low copy number DNA in this context. 
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4.5. Challenges with toxicogenetics interpretation 
 
The challenges in toxicogenetics are not only technical, but the genetic information it provides 
needs to be interpreted within the case context. Firstly, the result must be integrated with those 
from forensic toxicology and forensic pathology (Sajantila et al., 2010). This means that 
knowledge of pathophysiological conditions, concentration of drugs and their relative 
metabolites at the time of death, as well genetics results must be combined for such 
investigations (Sajantila et al., 2010). Additionally, fundamental research must still be 
conducted before toxicogenetics results can be routinely used as evidence in court, so that there 
is enough knowledge to render reliable interpretations. 
 
Toxicogenetic studies to date have established strong associations between genotype and 
phenotype for a limited number of cases (Koski et al., 2006). Research stated that genotype 
does not always translate to phenotype, but rather suggest an alternative explanation for CoD 
and/or MoD (Sajantila et al., 2010). Another issue with toxicogenetic studies is that a change 
in amino acid sequence of an enzyme does not directly indicate a change in phenotype. In 
addition variants around the coding regions of the DME genes can affect metabolism without 
having an effect on structure of the protein (Sajantila et al., 2010). This complicates 
interpretation of medico-legal genetics and as such, caution must be exercised. 
 
Some SNPs and/or haplotypes reported as prevalent in other populations remain to be fully 
investigated and understood in African populations as contradicting results have been found 
(Matimba et al., 2009). CYP2C9*2 and CYP2C9*3 for example, identified as rare alleles in 
African Americans were not found in the African population (Matimba et al., 2009). Although 
the data were reported for CYP2C9, the same can be inferred for CYP2D6 as they are similar 
in functionality. Llerena et al (2014) reported an uneven distribution of CYP2D6 studies around 
the world, with Africa highly underrepresented (LLerena et al., 2014). The lack of frequency 
data and functional studies regarding variations observed, often makes it difficult to predict 
what the variants mean for the deceased individual. Although this follow-up study did not 
assign haplotypes, this was done in the pilot study and could potentially be done in further 
studies. This will add to the currently available data on SNPs/haplotypes regarding South 
African population or Africa as a whole. 
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The presence of pseudogenes also causes problems with CYP2D6 genotyping (Endrizzi et al., 
2002). The CYP2D locus contains two pseudogenes CYP2D7 and CYP2D8 which are closely 
related and located to CYP2D6 (Gaedigk, 2013). This in turn presents challenges with primer 
design as well as with full gene sequencing and genotype interpretation (Yang et al., 2017). 
CYP2D6 is also susceptible to allele drop-out due to the fact that it is highly polymorphic 
(Scantamburlo et al., 2017). This is especially problematic when a phenotype is predicted from 
a genotype, as this might lead to phenotype misclassification (Scantamburlo et al., 2017). The 
large number of allelic variants as well as presence of structural and copy number variation has 
presented challenges with CYP2D6 genotype analysis (Gaedigk, 2013). 
 
4.6. Limitations, considerations and future work 
 
There were several limitations to this study, the first being that the selection criteria of cases 
excluded those with signs of decomposition. Decomposition is not uncommon in forensics, but 
the data from the current study does not provide insight into suitability of blood samples from 
these cases. However, the approach used in this study was chosen to first establish baseline 
data, which must be followed up with testing on more representative cases in the future. 
 
A current limitation in this study was the gap in storage time between analyses. Currently there 
are only two-time points were data has been collected, which limits the statistical analyses and 
modelling ability. Therefore, including more time points in the ongoing longitudinal nature of 
this study is warranted. 
 
Another limitation with this study was the small sample size of 30 and it is of utmost 
importance to increase the number of participants going forward, to represent the large and 
varied population of the WC and South Africa. One of the reasons for the small sample size in 
this study was that this study began as a pilot project, to demonstrate a proof of concept. 
Since the results shown in both studies (pilot and current) are promising, the study needs to 
be suitably expanded to generate statistically representative and reproducible results. In this 
regard, the ethical concerns pertaining to the use of post-mortem samples in research need to 
be discussed. Sampling from deceased individuals for research purposes is an important but 
sensitive matter, which needs to be conducted under a strict ethical framework and be 
strongly justified (Heathfield et al., 2017). This is mainly because one must obtain informed 
consent from grieving family members, and such individuals are vulnerable at the time they 
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are often approached for consent (Heathfield et al., 2017). In this larger study, informed 
consent was obtained from families following the strict ethical guidelines previously 
mentioned. 
 
The generation and feedback of genetic results is another area of ethical concern. The question 
raised was whether genetic research results should be shared with family members and if so, 
what information should be shared. Giving genetic results to living relatives is especially 
important if mutations are discovered which would have implications on the remaining family 
members. In such cases genetic counselling becomes a necessity, to elucidate the significance 
of the genetic results. Returning the results of genetic testing to remaining family members 
means that they can also get some form of closure, after understanding what may have caused 
or contributed to their loved one’s death (Bird, 2014). 
 
Lagay (2000), in a study based on health effects associated with pesticide exposure, described 
vulnerability of a population as one of the ethical concerns in toxicogenetic studies and stated 
that research is a foreign concept to the majority of the population (Lagay, 2000). Other issues 
raised included language barriers, which can hinder people’s ability to understand the research. 
These are some of the considerations which must be continually taken into account in ongoing 
research in this field. 
 
In this study, the variables of time and tube type accounted for 13 – 38% of variance in DNA 
concentration, purity and degradation. As such, it was hypothesised that other factors such as 
post-mortem interval (PMI), age and sex of the deceased possibly played a role in DNA 
quantity and quality and therefore should be investigated further. This information is available 
for the purposes of this study. 
 
In the case that blood is not available for genetic analyses, DNA may be obtained from stored 
formalin fixed paraffin-embedded (FFPE) tissue (if available). During post-mortem 
examinations, human tissue samples are routinely collected and subjected to a fixation and 
preservation procedure for histological analysis and to allow for long-term archival storage 
(Hansen et al., 2014). Although DNA can be obtained from FFPE tissue, it was reported that 
the material was often degraded and cross-linked which made it difficult to amplify by PCR 
(Baak-Pablo et al., 2010). Although FFPE was not the focus of this study the sample type can 
be investigated for future studies. 
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Future work should also bear in mind the possible optimisation required for Sanger sequencing 
in samples with low concentrations, as well as expand this study to investigation other DMEs. 
This study has focused on one CYP enzyme of which there are many enzymes that can 
metabolise drugs and most drugs are metabolised by more than one CYP. Therefore this, 
coupled with multiple drugs affecting metabolism competitively becomes more complex. This 
might need to be taken into consideration in possible future work. 
 
 
4.7.  Conclusion 
 
DNA quality and quantity were previously assessed approximately 16 weeks after sample 
collection and showed that no additive tube (red-top) samples were suitable for genetic 
analyses. In this study, at approximately 48 weeks after sample collection, the DNA quantity 
and quality were assessed again. DNA concentration and purity had significantly decreased for 
red-top tube samples, so much so that PCR needed to be re-optimised. Despite these efforts 
sequencing data was of poorer quality for assessing SNPs in a single case example. 
 
In contrast, DNA from NaF/C2K2O4 tube (grey-top) samples had an unexpected increased 
concentration with time, as measured by qPCR, the mechanism which remains unknown. Three 
out of five of the grey-top samples produced sequencing data which was suitable for assessing 
SNPs, which was an improvement compared to the first assessment in the pilot study. 
 
The aim of this study was to assess the quantity and quality of DNA from blood samples, which 
were collected in tubes with NaF/C2K2O4 (grey-top tubes) and tubes without preservative (red- 
top tubes) for toxicological screening and stored for one year. This aim has been achieved and 
has added to the body of knowledge concerning the pre-analytical factors associated with 
toxicogenetics, and in particular the considerations surrounding the quality of the genetic 
results. 
 
Considering the results from both the pilot study and this follow up study, both tube types may 
pose challenges for toxicogenetics and further work is required to further optimise processes 
as well as assess DNA quantity and quality over longer periods of time. Additional longitudinal 
analysis therefore must be conducted on these samples to monitor trends over time, as well as 
these results verified in a larger sample size. These results provide important information in 
the understanding of DNA in blood samples stored in different tubes over time. 
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Forensic toxicologists are often asked to provide information concerning the role 
drugs/substances played in impairment or death. Furthering our understanding of 
toxicogenetics and individual variation in metabolism of relevant drugs (such as prescribed 
medicinal and recreational drugs of abuse) and associated pharmacokinetic variation may assist 
in strengthening these interpretations as a whole. Research in these areas may improve our 
understanding of the role of inter-individual metabolism and genetic variants in interpreting 
drug concentrations determined from post-mortem forensic toxicological analysis.
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APPENDICES 
APPENDIX A: CYP2D6 primers and the exons they belong to. 
Table A1: Target exons of CYP2D6 and the corresponding primers. 
 
Target CYP2D6 
exon 
Primer sequence 
(5’ to 3’) 
Primer 
Direction 
Length 
(bp) 
GC 
content 
(%) 
Predicted 
Tm (0C) 
Product 
Size 
(bp) 
A 1.1 GCCATCATCAGCTCCCTT Forward 18 55.6 54.9 954 
CCTATTTGAACCTTGGACGA 
(previously 1.2 R) 
Reverse 20 45.0 52.1 
C 1.3 CTTCCACCTGCTCACTCC Forward 18 61.1 55.3 314 
TCTGTCTCTGTCCCCACC Reverse 18 61.7 56.1 
D 2 and 3 GTGGATGGTGGGGCTAAT Forward 18 55.6 54.6 483 
ACTCCTCGGTCTCTCGCT Reverse 18 61.1 57.7 
E 4 CCCGTTCTGTCTGGTGTAG Forward 19 57.9 54.9 266 
AGCCTCCCCTCATTCCTC Reverse 18 61.1 56.3 
F 5 and 6 GTTCTGTCCCGAGTATGC Forward 18 55.6 52.7 334 
CCTGACACTCCTTCTTGC Reverse 18 55.6 52.9 
G 7 CATAGGAGGCAAGAAGGAG Forward 19 52.6 52.1 382 
TGGTGGCATTGAGGACTA Reverse 18 50.0 53.1 
H 8 ATCCTAGAGTCCAGTCCC Forward 18 55.6 52.3 534 
ACTACCACATTGCTTTATTGTAC Reverse 23 34.8 51.0 
I 9 TATCACCCAGGAGCCAGG Forward 18 61.1 56.3 520 
CCCACATGCCAGGACAAT Reverse 18 55.6 55.4 
 
Note: Targets A and C are not full-length exons; they are parts of exon 1 of CYP2D6, 
combining to give the full length of the exon. Targets D and F are stretches of DNA 
incorporating exons 2 and 3, and exons 5 and 6 of CYP2D6, respectively. 
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APPENDIX B: Median values for 2017 and 2018 
 
Tube type Concentration DI A260/280 A260/230 
R-No-Tox: 2017 25.81 0.7957 1.832 1.292 
R-No-Tox: 2018 0.855 1.095 1.527 0.7225 
R-Tox: 2017 9.850 0.6752 1.667 1.312 
R-Tox: 2018 0.890 1.074 1.53 0.6275 
G-No-Tox: 2017 20.26 0.888 1.845 1.577 
G-No-Tox: 2018 37.18 0.8785 1.617 1.24 
G-Tox: 2017 22.93 0.8426 1.767 1.665 
G-Tox: 2018 21.46 0.900 1.742 1.1475 
P-No-Tox: 2017 20.92 0.8540 1.855 1.522 
P-No-Tox: 2018 6.646 1.221 1.58 0.865 
Page | 56 
 
S 
Exon 1.3: Forward orientation 
APPENDIX C: Quality assessment by Sanger sequencing 
 
Exon 1.1: Forward orientation 
 
 
 
GT 
 
 
 
 
RT 
 
 
 
 
 
Size (bp) 
 
Reverse Orientation 
 
 
 
GT 
 
 
 
 
RT 
 
 
 
 
 
Size (bp) 
Figure C1: A portion of DNA sequence for exon 1.1 for grey and red-top samples. The figure 
shows the forward and reverse complements for red and grey top samples. Following DNA 
extraction, five targets of CYP2D6 were amplified using red and grey samples for case 22. The 
samples were then sent to the Central DNA Sequencing Facility at the University of Stellenbosch 
for sequencing. 
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Exon 1.3: Forward orientation 
 
 
 
 
GT 
 
 
 
 
RT 
 
 
 
 
 
 
 
Size (bp) 
Reverse orientation 
 
 
 
 
GT 
 
 
 
 
 
 
 
RT 
 
 
 
 
 
Size (bp) 
 
Figure C2: A portion of DNA sequence for exon 1.3 for grey and red-top samples. The 
figure shows the forward and reverse complements for red and grey top samples. Following 
DNA extraction, five targets of CYP2D6 were amplified using red and grey Tox samples for 
case 22. The samples were then sent to the Central DNA Sequencing Facility at the University 
of Stellenbosch for sequencing 
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Exon 4: Forward orientation 
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Figure C3: A portion of DNA sequence for exon 4 for grey and red-top samples. The 
figure shows the forward and reverse complements for red and grey top samples. Following 
DNA extraction, five targets of CYP2D6 were amplified using red and grey Tox samples for 
case 22. The samples were then sent to the Central DNA Sequencing Facility at the 
University of Stellenbosch for sequencing. 
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Exon 8: Reverse orientation 
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Figure C4: A portion of DNA sequence for exon 8 for grey and red-top samples. The figure 
shows the reverse complements for red and grey top samples. Following DNA extraction, five 
targets of CYP2D6 were amplified using red and grey post-tox samples for case 22. The samples 
were then sent to the Central DNA Sequencing Facility at the University of Stellenbosch for 
sequencing. 
Si
gn
al
 in
te
n
sit
y 
Si
gn
al
 in
te
n
sit
y 
Page | 60 
 
Exon 9: Forward orientation 
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Figure C5: A portion of DNA sequence for exon 9 for grey and red-top samples. The 
figure shows the forward reverse complements for red and grey top samples. Following 
DNA extraction, five targets of CYP2D6 were amplified using red and grey post-tox samples 
for case 22. The samples were then sent to the Central DNA Sequencing Facility at the 
University of Stellenbosch for sequencing. 
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APPENDIX D: Primary PCR for red-top tube samples (case 22) 
Figure D1: Primary PCR for red-top tube samples. PCR for red-top samples using 5 µl 
of DNA template resulted in faint bands for exon 1.1: lane B. There was no visible band for 
exon 8: lane D. Exon 1.3 and 9 produced visible bands (lane C and E, respectively). 
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APPENDIX E1: Ethics approval letter for pilot study 
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APPENDIX E2: Ethics approval letter for follow-up study 
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